PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “CARCINOMA, BASAL CELL”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1987

DNA repair synthesis in fibroblast strains from patients with actinic keratosis, squamous cell carcinoma, basal cell carcinoma, or malignant melanoma after treatment with ultraviolet light, N-acetoxy-2-acetyl-aminofluorene, methyl methanesulfonate, and N-methyl-N-nitrosourea.

Fibroblast strains derived from skin biopsies of patients with actinic keratosis (6), malignant melanoma (18), squamous cell carcinoma (11), and basal cell carcinoma (12) were investigated for DNA repair synthesis, with 16 fibroblast strains for normal donors as controls. Cells were exposed to UV light, the "UV-like" carcinogen (Ac)2ONFln, and the methylating carcinogens MeSO2OMe and MeNOUr. Dose-response experiments, which included 10 dose levels, were performed, the data analyzed by linear regression, and the slope of the regression line (term: G0) used as a measure of DNA repair synthesis. The mean experimental variability of G0 of individual fibroblast strains was 9.5%-15.4%, depending upon exposure. For comparison of all cell strains belonging to the same skin malignancy group with those of the control group, G0 values of the individual strains were combined to yield group-specific weighted mean G0 values. In addition, the capacity to incise UV-damaged DNA was measured in 24 cell strains from patients with skin tumors using the alkaline elution technique. For quantitating DNA-incising capacity, the initial velocities of the elution curves were plotted versus the UV dose, and the slope of the resulting regression line was used to obtain the characteristic value E0. The mean experimental variability of E0 of individual strains was +/- 22%. These E0 values were combined to yield weighted mean values of groups. The fibroblast strains in the groups of patients with actinic keratosis and malignant melanoma were found to have normal mean G0 values when DNA repair synthesis was challenged with UV light or one of the three carcinogens. However, the squamous cell carcinoma group exhibited significantly lower mean G0 values after treatment with UV light (82% that of normal donors), (Ac)2ONFln (70%), MeSO2OMe (70%), and MeNOUr (69%). The basal cell carcinoma group showed significantly diminished repair synthesis upon treatment with UV light (81% that of normal donors) and MeSO2OMe (67%). In contrast to these findings, in no skin malignancy group was post UV DNA-incising capacity (E0) significantly diminished, although it should be noted that group sizes were only half as large as for G0 determinations. These data may be interpreted as indicating that DNA excision repair is impaired in fibroblast strains from patients with squamous cell carcinoma and-to a lesser extent-basal cell carcinoma.(ABSTRACT TRUNCATED AT 400 WORDS)

Acetoxyacetylaminofluorene↗
PubMed1993

[Squamous cell carcinoma, basal cell carcinoma].

In Japan the regimen with peplomycin has been mainly used for the treatment of squamous cell carcinoma (SCC). But recently, a regimen with cisplatin, particularly the combination of cisplatin and adriamycin (CA chemotherapy) has been used for the treatment of SCC, and a better prognosis has resulted Since CA chemotherapy is very effective for not only SCC, but also basal cell carcinoma (BCC), we think it is a prominent neoadjuvant therapy for SCC and BCC. We have used CA chemotherapy for multiple lung metastasis of BCC over the past six years, and three times PR was obtained, with survival so far.

Adult↗
PubMed1989

Activity of the proteolytic enzyme guanidinobenzoatase in human basal cell carcinoma.

Basal cell carcinomas exhibit a characteristic pattern of aggressive invasion from the basal layer of skin epithelial cells. These tumour cells possess an enzyme, guanidinobenzoatase (GB), which is known to be associated with cell migration. The enzyme is inhibited by a fluorescent probe, 9-aminoacridine, and this can be used to locate cells possessing active guanidinobenzoatase. All basal cell carcinoma cells in frozen sections were located by their ability to bind 9-aminoacridine. Extracts of most tissues were shown to contain inhibitors of the GB associated with basal cell carcinoma cells. Extracts of skin, however, failed to inhibit this tumour-associated GB. The significance of these results is discussed in terms of the pathophysiology of basal cell carcinomas.

Aminacrine↗
PubMed2000

Incidence of perineural invasion in histologically aggressive types of basal cell carcinoma.

Basal cell carcinoma is generally an indolent form of skin cancer. Morpheaform, infiltrative, and sclerosing types are more aggressive tumors. The incidence of perineural invasion in aggressive types of basal cell carcinoma has not been previously described. We studied aggressive basal cell carcinomas for the presence of perineural invasion. Between 1995 and 1998, the histopathologic diagnosis of basal cell carcinoma was made on 5,097 specimens at Dartmouth-Hitchcock Medical Center. Of this total, 507 were classified as sclerosing, infiltrative, or morpheaform. Perineural invasion was found in 15 of the 507 cases. Of these 15 cases, 12 were from the face, and 3 from the back; 13 were recurrent, and 2 were primary lesions. The mean age of patients at diagnosis was 71 years. We found 9.9% of all basal cell carcinomas at our institution to be aggressive types. We found an incidence of perineural invasion of 3% in the aggressive basal cell carcinoma types. This incidence approaches that reported by others for cutaneous squamous cell carcinomas.

Aged↗
PubMed2002

Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients.

Psoralen + ultraviolet A-treated psoriasis patients are at increased risk for squamous cell carcinomas and basal cell carcinomas; however, the incidence and risk factors associated with second squamous cell carcinomas and basal cell carcinomas in this population are not well qualified. Incidence and risk factors for second squamous cell carcinomas and basal cell carcinomas were studied in a cohort of 1380 psoralen + ultraviolet A-treated psoriasis patients prospectively followed for over 20 y; 264 had a squamous cell carcinoma and 258 a basal cell carcinoma after beginning psoralen + ultraviolet A therapy. After a first squamous cell carcinoma, the risk of a second squamous cell carcinoma was 26% at 1 y, 62% at 5 y, and 75% at 10 y. Risk increased with high psoralen + ultraviolet A exposure prior to the first squamous cell carcinoma (hazard ratio 3.32, 95% confidence interval 1.53, 7.18). Higher rates of post-first squamous cell carcinoma psoralen + ultraviolet A treatment also were associated with greater risk (hazard ratio 1.56 for every additional 10 treatments per year for patients with low pre-first squamous cell carcinoma psoralen + ultraviolet A exposure, 95% confidence interval 1.35, 1.81). Patients exposed to high levels of tar and/or ultraviolet B before a first squamous cell carcinoma were also at higher risk (hazard ratio 1.72, 95% confidence interval 1.14-2.60). Risk of a second basal cell carcinoma was 21% at 1 y, 49% at 5 y, and 61% at 10 y. There was some evidence that high exposure to psoralen + ultraviolet A before a first basal cell carcinoma was associated with increased risk of second basal cell carcinoma (hazard ratio 1.45, 95% confidence interval 0.97-2.17). Higher post-first tumor psoralen + ultraviolet A treatment rates also increased risk (hazard ratio 1.24 for every additional 10 treatments per year, 95% confidence interval 1.06-1.47). Psoralen + ultraviolet A-treated psoriasis patients appear to have a greatly increased incidence of second squamous cell carcinoma compared with the general population. Patients who develop a squamous cell carcinoma after starting psoralen + ultraviolet A therapy should be closely monitored for a subsequent squamous cell carcinoma.

Aged↗
PubMed2001

Signet ring cell basal cell carcinoma: a basal cell carcinoma with myoepithelial differentiation.

Basal cell carcinoma (BCC) can show a variety of routes of differentiation, but myoepithelial differentiation has rarely been described. We describe a case of BCC showing histologic and immunohistochemical features of myoepithelial differentiation. Histologically, the lesion showed well-demarcated tumor nodules composed of two different components. One component was typical of BCC, and the other component was composed of tumor cells containing abundant cytoplasm, eccentric nuclei, and no peripheral palisading, with scattered signet ring-shaped cells. Immunohistochemically, the tumor cells in the typical BCC component stained with CKAE1/AE3 and smooth muscle actin (SMA), but not with S-100 protein. They stained weakly with CAM5.2, epithelial membrane antigen, and glial fibrillary acidic protein (GFAP). The tumor cells in the other component stained strongly with CKAE1/AE3 and SMA, moderately with epithelial membrane antigen and GFAP, and weakly with CAM5.2. In a small area, the tumor cells stained with S-100 protein.

Aged↗
PubMed1997

Basal cell carcinoma.

Basal cell carcinoma is the commonest malignancy in Caucasians with incidence rates of 300 per 100,000 reported in the USA. Rates are increasing at over 10% per year leading to a lifetime risk of 30%. Although mortality is low, the disease is responsible for considerable morbidity and places a substantial burden on health service provision in the UK. Furthermore, lesions may recur and patients often develop multiple tumours giving major implications for treatment and follow-up. Four main types of basal cell carcinoma are seen: nodulo-ulcerative; pigmented; morpheaform and superficial. Diagnosis is by histological evaluation although many tumours have a characteristic clinical appearance. The differential diagnosis is large. Identified risk factors include male gender, skin type 1, red/blonde hair and increasing age. Patients with basal cell carcinoma are more likely to develop malignant melanoma and squamous cell carcinoma but it is still unclear whether there is a link with internal malignancy. The main treatment modalities are surgery and radiotherapy. Each has advantages and disadvantages. The choice of treatment depends on many factors. Principles of treatment include identification of high-risk patients to enable early detection, complete removal of the lesion, and careful follow-up to detect recurrence or new lesions. Approximately 10% of tumours recur, depending on site, size and treatment modality. Metastatic basal cell carcinoma and the association of ultraviolet radiation to basal cell carcinoma risk are reviewed.

Basal Cell Carcinoma↗
PubMed1999

[Basal cell carcinoma].

Basal cell carcinoma is the most frequent of all cancers. Its incidence has risen those last decades because of the increase in sun exposure habits. People with light skin complexion are particularly at risk. Ionizing radiations, arsenicism, various genodermatoses (Gorlin syndrome, xeroderma pigmentosum, nevus sebaceous) are other pre-disposing factors. Basal cell carcinoma usually present as small lesion with a pearly border and telangiectasias. Other clinical types must also be recognized such as the nodular, the infiltrative, the superficial and the pigmented forms. They are usually located on the head and trunk. The prognosis of basal cell carcinoma is usually good since they can be cured by surgical excision and because they usually do not metastasize. However, large, multiple or recurrent basal cell carcinomas can be difficult to treat. In these cases, cryosurgery, radiotherapy or intralesional interferon-alfa may be needed.

Basal Cell Carcinoma↗
PubMed1996

Giant polypoid basal cell carcinoma.

Basal cell carcinomas may attain giant proportions due primarily to recurrence and neglect. Giant basal cell carcinomas (5 cm or more in diameter) are of four clinical subtypes: noduloulcerative, morpheaform, superficial, and polypoid. We report a patient with a typical polypoid lesion of fifteen years' duration on his shoulder. The polypoid variant differs from other giant basal cell carcinomas in several important ways: the polypoid lesions appear on the torso or extremity, rather than the head or neck, as beefy-red, friable, exophytic masses for which the patient typically has had no previous treatment; the histologic type tends to be nonaggressive; and finally, the lesions are amenable to surgical cure with low metastatic potential.

Adult↗
PubMed1984

Metastatic basal cell carcinoma.

Basal cell carcinoma rarely metastasizes. There are over 130 reported cases, 70% of which involve lymph nodes. In many cases a large, chronic, neglected or inadequately treated basal cell carcinoma preceded the metastasis. We report a case in which a basal cell carcinoma of the cheek metastasized to cervical lymph nodes.

Adult↗
PubMed2004

Atypical presentation of metastatic basal cell carcinoma.

Basal cell carcinoma is an indolent, slow-growing tumor that rarely metastasizes. Approximately 70% of tumors occur in the head and neck regions. If a basal cell tumor metastasizes, it usually spreads to the regional lymph nodes first, followed by the lungs. We describe a patient with basal cell carcinoma of the right lower extremity with skin metastases. Skin biopsy of one tumor revealed fibroepithelioma of Pinkus, a rare variant of basal cell carcinoma.

Basal Cell Carcinoma↗
PubMed1998

Multiple pigmented basal cell carcinomas.

Basal cell carcinoma is the most common of all skin cancers and the most prevalent one among Caucasians. Rarely, these tumors are seen in other races. We report a 77-year-old Korean woman who presented with multiple darkly pigmented enlarging nodules on her scalp, face, trunk, and extremities. The patient had first noted a 6-mm pigmented lesion on her left eyebrow 10 years previously. Since then, other lesions had appeared in many locations on her body. She had been otherwise healthy and without a history of exposure to arsenic or radiation. There was no family history of skin cancer, xeroderma pigmentosum, or basal cell nevus syndrome. On physical examination, multiple darkly pigmented dome-shaped papules and nodules were present on her scalp, face, right forearm, lower abdomen, and inguinal areas. They ranged in size from 0.5 mm to 2 cm. The larger ones showed central ulceration. Multiple biopsy specimens from different sites showed pigmented basal cell carcinomas. Clinically, there was no evidence of nevus sebaceus, xeroderma pigmentosum, basal cell nevus syndrome, or immunodeficiency. Clinical workup including chest radiography, abdominal ultrasound, bone scan, and brain computerized axial tomography scan did not demonstrate primary or secondary tumors. The results of serologic and hematologic tests were also within normal limits. This is an unusual case report of multiple pigmented basal cell carcinomas in an Asian woman without any predisposing risk factors.

Aged↗
PubMedDate not supplied

Metastasizing auricular basal cell carcinoma.

Basal cell carcinoma represents the most common skin cancer and involves the head and neck area in 80% to 85% of all patients treated. Despite their frequent occurrence, metastatic spread from these tumors is rare. This paper presents a case of a patient who had a metastasizing basal cell carcinoma. Despite control of primary disease by radical surgery and adjunctive irradiation, bony metastasis was found within nine months of therapy. Palliative therapy was given, but the patient died five months later. The pathophysiology of the metastasizing basal cell carcinomas is described, and a rationale for therapy presented.

Bone Neoplasms↗
PubMed1988

Signet-ring clear-cell basal cell carcinoma.

Basal cell carcinoma displays a myriad of histopathologic variants, some of which are related to the different lines of differentiation, vis-a-vis, squamous, pilar, eccrine, or sebaceous. We herein report an example of a rare signet-ring, clear-cell variant. Our diagnosis is primarily based on the histopathologic features of the tumor, namely, the dermal nests of tumor cells with peripheral palisading and focally retracted fibroblastic stroma. Several nests are folliculocentric. The tumor cells are glycogen-rich, mucin-negative, pankeratin-positive, cytokeratin-negative, S100 protein-negative, and carcinoembryonic antigen-negative. Based on the histopathology and the results of the special stains we propose that the signet-ring clear-cell variant of basal cell carcinoma is differentiating in the direction of the outer root sheath cells of the pilar structure.

Aged↗
PubMed1981

Cancer of the skin in blacks: a review of 128 patients with basal-cell carcinoma.

Basal cell carcinoma in black persons is generally believed to be rare, with cases only sporadically reported. Information about 148 basal cell carcinomas found in 128 black patients who were seen at Charity Hospital of Louisiana, New Orleans, between 1948 and 1979, was reviewed. As in whites, most of the tumors occurred on the sun-exposed areas of the head and neck.

Adolescent↗
PubMed2004

[Polypoid basal cell carcinoma].

Basal cell carcinoma, the most common malignant neoplasm of the skin, has many clinical and histologic variants. We report about a 58-year-old patient with a rarely described, polypoid variant of this tumor. Polypoid basal cell carcinoma differs clinically from other variants by being exophytic and pedunculated and, histologically, the tumor aggregations are restricted only to the polypoid part.

Basal Cell Carcinoma↗